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The activation of cyclin-dependent protein kinases
(Cdks) is dependent upon site-specific phosphorylation
and dephosphorylation reactions, as well as positive
and negative regulatory subunits. The human Cdk-acti-
vating protein kinase (Cak1) is itself a Cdc2-related cy-
clin-dependent protein kinase that associates with cy-
clin H. The present study utilized specific anti-Cak1
antibodies and immunoaffinity chromatography to
identify additional Cak1-associated proteins and poten-
tial target substrates. Immunoprecipitation of metabol-
ically labeled human osteosarcoma cells revealed a
number of Cak1-associated proteins, including p95, p37
(cyclin H), and a 35-kDa protein that was further char-
acterized herein. Microsequence analysis obtained after
limited proteolysis revealed peptide fragments that are
similar, but not identical to, human and yeast cyclins,
thus identifying p35 as a cyclin-like regulatory subunit.
The greatest sequence similarity of human p35 is with
Mcs2, a yeast cyclin that is essential for cell cycle pro-
gression. Immunoaffinity chromatography performed
under nondenaturing conditions afforded the isolation
of enzymatically active Cak1 from cell lysates, enabling
studies of kinase autophosphorylation and comparative
substrate utilization. Immunoaffinity-purified Cak1
phosphorylated monomeric Cdc2 and Cdk2, but not
Cdk4; the phosphorylation of both Cdc2 and Cdk2 were
increased in the presence of recombinant cyclin A.
These studies indicate that the Cak1 catalytic subunit,
like Cdc2 and Cdk2, associates with multiple regulatory
partners and suggests that subunit composition may
be an important determinant of this multifunctional
enzyme.
Critical transitions in the eukaryotic cell cycle are regulated
by patterns of protein phosphorylation events governed pre-
dominantly by the catalytic activities of cyclin-dependent pro-
tein kinases (Cdks)1 (Norbury and Nurse, 1992; Meyerson et
al., 1992; Reed, 1992; Pines, 1993; Dorée and Galas, 1994). The
activities of these Cdks are themselves regulated by site-spe-
cific phosphorylation-dephosphorylation reactions (Krek and
Nigg, 1991; Norbury et al., 1991; Solomon, 1993) as well as the
association with positive (i.e. cyclins) (Hunt, 1991; Wu et al.,
1993; Sherr, 1993; Draetta, 1994) and negative (i.e. Cdk inhib-
itors) (Elledge and Harper, 1994; Peter and Herskowitz, 1994;
Xiong et al., 1993) regulatory subunits. An essential phospho-
regulatory site, deduced from genetic studies in yeast, was
identified within the T-fold of kinase subdomain VIII (Marcote
et al., 1993; DeBondt et al., 1993) of Cdc2 (at Thr-161) and Cdk2
(at Thr-160) and whose phosphorylation is required for the
generation of Cdc2/Cdk2 kinase activity (Krek et al., 1992; Gu
et al., 1992; Connell-Crowley et al., 1993). Subsequent studies
have identified a distinctive Cdc2/Cdk2-activating protein ki-
nase (CAK) in Xenopus oocytes, MO15 (Shuttleworth et al.,
1990; Poon et al., 1993; Solomon et al., 1993), and human tumor
cells (Solomon et al., 1993; Williams et al., 1993a, 1993b). The
catalytic subunit of the human CAK (Cak1) has been cloned
and is found to be structurally related to Cdc2(Hs) (Wu et al.,
1994). Human Cak1 has been shown to complex with at least
one regulatory subunit, cyclin H (Fisher and Morgan, 1994;
Mäkelä et al., 1994), revealing a vectorial cascade of cyclin-de-
pendent protein kinases.
Other recent studies suggest that Cak1 functions in tran-
scriptional regulation, DNA repair, and tumor suppression, in
addition to its role in regulating cell cycle progression.
However, numerous questions remain regarding the subunit
configuration(s), biochemical activation, substrate specificity,
and physiological targets of this key regulatory enzyme. Pro-
nounced disparities in the published literature concerning the
molecular mass of the Cak1 complexes (Solomon et al., 1992;
Poon et al., 1993; Williams et al., 1994; Wu et al., 1994), the
nature and identity of its regulatory subunit(s) (Mäkelä et al.,
1994; Tassan et al., 1994), the phosphorylation of putative
target substrates, including monomeric Cdc2 (Dorée and Galas,
1994; Fisher and Morgan, 1994) and Cdk4 (Kato et al., 1994;
Matsuoka et al., 1994), and the regulation of its enzymatic
activity (Fisher and Morgan, 1994; Matsuoka et al., 1994; Wil-
liams et al., 1994), suggest that our understanding of this key
regulatory enzyme system is still incomplete.
Using the deduced amino acid structure of (Hs)Cak1 (Wu et
al., 1994), we developed anti-peptide antibodies that are selec-
tive for the p42cak1 subunit and have characterized the per-
formance of these antibodies for both immunoprecipitation and
Western blotting. In this study, we used anti-Cak1 antibodies
and immunoaffinity chromatography to investigate the enzyme
activities of purified Cak1 and to further characterize Cak1-
associated proteins. In addition to verifying high molecular
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weight complexes reported previously (Williams et al., 1993a,
1993b) and the association of a 37-kDa protein identified as
cyclin H (Mäkelä et al., 1994; Fisher and Morgan, 1994), we
detected a distinctive 35-kDa protein in association with
p42cak1. Isolation, fragmentation, and microsequence analysis
of p35 revealed that this Cak1-associated protein exhibits
amino acid sequence homologies to human cyclin H and yeast
Mcs2; indicating that p35 is indeed a cyclin-like regulatory
subunit that is related to, but distinct from, cyclin H.
EXPERIMENTAL PROCEDURES
Materials
Cell Cultures and Cell Synchronization—Human MG-63 and TE-85
osteosarcoma cells were obtained from the American Type Cell Culture
Collection (ATCC; Rockville, MD). The MG-63 cells were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum (Life
Technologies, Inc.), penicillin, and streptomycin, and the TE-85 cells
were maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and antibiotics, at 37 °C, in 5% CO2
humidified air. MG-63 cells were synchronized by serum deprivation, as
described previously (Carbonaro-Hall et al., 1993). Hela S-3 cells, grown
as large scale suspension cultures, were obtained from the University of
Southern California Norris Comprehensive Cancer Center, frozen in
liquid nitrogen, and stored at 270 °C prior to use.
Recombinant Plasmids and Synthetic Peptides—The expression vec-
tors encoding the glutathione S-transferase fusion proteins glutathione
S-transferase-Cdc2 and glutathione S-transferase-Cdk2, and the
epitope-tagged HA-Cdk4, have been described elsewhere (Connell-
Crowley et al., 1993). Polymerase chain reaction-derived full coding
sequences of human cyclin H (Fisher and Morgan, 1994; Mäkelä et al.,
1994) were ligated into the pET-28 expression vector (Novagen) and
maintained in XL Blue strain of E. coli. For expression of the His-tagged
human cyclin H fusion protein, the plasmid was transformed into
BL21(DE3) strain E. coli, and recombinant protein expression was
induced by incubation in the presence of isopropyl-1-thio-b-D-galacto-
pyranoside. Anti-peptide antisera, directed against the first 15 amino
acids of human cyclin H (Fisher and Morgan, 1994) was raised in
rabbits. The synthetic peptide corresponding in sequence to residues
151–170 of the human p34cdc2 (Lee and Nurse, 1987), as well as the
Ala-162 congener, was chemically synthesized and coupled to Affi-Gel
10 as described previously (Williams et al., 1994).
Methods
Metabolic Labeling, Immunoprecipitation, and Immunoblotting—
For 35S labeling of cellular proteins, TE-85 and MG-63 osteosarcoma
cells in log phase growth were washed twice with prewarmed methi-
onine-free and cysteine-free Dulbecco’s modified Eagle’s medium (ICN)
and were preincubated in this media supplemented to 0.5% dialyzed
fetal bovine serum (Life Technologies, Inc.) for 30 min at 37 °C.
[35S]Met/Cys (1 mCi/ml; ICN) was added directly to the culture media to
effect a final concentration of 100 mCi/ml, and the cell cultures were
incubated for 4 h at 37 °C. Following metabolic labeling, the cells were
washed twice to remove exogenous label prior to cell lysis, immunopre-
cipitation, and visualization of the immune complexes by SDS-PAGE
and autoradiography. Cell lysates were prepared from fresh monolayer
cultures as follows. The cells were washed twice in Hanks’ balanced salt
solution and lysed in a small volume (1 ml/75-cm2 culture flask) of IP
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EGTA, 25 mM
sodium fluoride, 25 mM b-glycerolphosphate, 0.1 mM sodium orthovana-
date, 0.1 mM phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin, 0.2%
(v/v) Triton X-100, 0.3% (v/v) Nonidet P-40) and clarified by centrifu-
gation (20,000 3 g) for 10 min at 4 °C. The supernatant was collected for
Western blotting, in vitro kinase assays, immunoprecipitation studies,
and column chromatography.
For immunoprecipitations, MG-63 and TE-85 cells were cultured and
lysed as described above, and the lysate was clarified by incubation with
50 ml (1:1 slurry in (13) PBS) of protein A-Sepharose CL-4B on ice for
15 min. Immunoprecipitations and affinity precipitations were per-
formed by incubating aliquots of the precleared lysate (supernatant)
with either no antibodies (control), specific antibodies, or specific pep-
tide-blocked antibodies for 20 min in ice with periodic mixing. The
resulting immune complexes were collected by the addition of 50 ml (1:1
slurry in (13) PBS) of protein A-Sepharose CL-4B, incubation in ice for
20 min, followed by centrifugation. After washing each pellet 4 times
with 750 ml of ice-cold Fast Q Buffer (20 mM Tris-HCl, pH 7.6, 1 mM
dithiothreitol, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 5
mg/ml leupeptin, 0.1 mM sodium orthovanadate) containing 50 mM
NaCl, and once in 750 ml of ice-cold kinase assay buffer, each pellet was
resuspended in 50 ml of (13) SDS sample buffer (62.5 mM Tris-HCl, pH
6.8, 40 mM dithiothreitol, 2% SDS, 0.025% bromphenol blue, 10% glyc-
erol) containing 10 mM N-ethylmaleimide (to minimize dissociation of
IgG chains), heat-denatured for 2 min at 95 °C, and the solubilized
proteins were analyzed by SDS-PAGE and Western blotting, as de-
scribed by Williams et al. (1992). The specific immunoreactivity of the
newly developed anti-Cak1 antibodies were validated by competition of
the antibody with the immunizing peptide as follows: approximately
400 mg of the immunizing peptide was mixed with anti-Cak1 IgG and
preincubated for 30 min at 30 °C prior to separate parallel incubations
of both blocked and nonblocked antibodies for 30 min on Western blots.
The resulting Western blots were developed under identical conditions.
Development and Application of Anti-Cak1 Antibodies—The C-termi-
nal amino acids (residues 328–346) of Cak1 were chemically synthe-
sized (Microchemical Core Facility, University of Southern California
Norris Cancer Center) and conjugated to KLH (Pierce, Rockford, IL) for
the immunization of rabbits to raise antisera directed against Cak1.
Portions of the collected antisera were used to prepare two subsets of
polyclonal antibodies: an affinity-purified fraction and an IgG fraction.
To generate the affinity-purified polyclonal antibodies, the antigenic
Cak1 peptide was coupled to Affi-Gel 10 (Bio-Rad, Richmond, CA) beads
preequilibrated in 20 mM KPO4, pH 7.4, at room temperature, with
gentle rocking for 2 h. The Affi-Gel beads were collected by centrifuga-
tion (3000 rpm 3 5 min), and the reaction was quenched by the addition
of 0.2 M ethanolamine and then transferred to a small column and
washed with 20 volumes of filtered (13) phosphate-buffered saline.
Anti-Cak1 antisera was diluted 1:4 in 1 3 PBS, filtered through 0.45
mm, and passed over the Affi-Gel beads 3 times. The beads were washed
extensively with 10 volumes filtered (13) PBS, and the anti-Cak1
antibodies were eluted using 0.1 M glycine-HCl, pH 2.7, collected in
0.5-ml fractions. The fractions were monitored for protein content (Bio-
Rad), and those containing affinity-purified antibodies were pooled and
aliquoted for storage at 220 C until use. To purify polyclonal anti-Cak1
IgG fractions, protein A-Sepharose CL-4B (1 ml bed volume) was equil-
ibrated with 20 volumes of 100 mM Tris-HCl, pH 8.0. Anti-Cak1 anti-
sera was adjusted to pH 8, diluted 1:4 with equilibration buffer, and
filtered through 0.45 mm for extraction by protein A-Sepharose CL-4B
as above. The antisera was passed over the resin twice, and the resin
was washed with 10 volumes of 100 mM Tris-HCl, pH 8.0, followed by 10
volumes of 10 mM Tris-HCl, pH 8.0, before eluting with 100 mM glycine,
pH 3.0. Fractions containing IgGs were pooled, aliquoted for later use,
and stored at 220 °C.
Immunoaffinity Chromatography—To prepare an anti-Cak1 immu-
noaffinity column, 1 ml (bed vol) of protein A-Sepharose CL-4B resin
was equilibrated in 100 mM Tris-HCl, pH 8.0, and several ml of anti-
Cak1 antisera was passed over it twice. The resin was washed exten-
sively with 0.1 M sodium borate, pH 9.0, and dimethyl pimelimidate
(Pierce Chemicals) was added to 20 mM to covalently bind the IgG to the
resin (30 min, at room temperature, with gentle rocking). The resin was
collected by centrifugation, washed with 0.2 M ethanolamine, pH 8.0,
and allowed to block in ethanolamine for 2 h. The resin was again
collected by centrifugation (2500 rpm 3 5 min) and washed extensively
with filtered (13) PBS, pH 7.4. The column was preeluted with 100 mM
glycine, pH 3.0, to remove noncovalently bound IgG prior to immuno-
affinity chromatography.
Hela S-3 cells (5–7 g pellets) were stored at 270 °C until use. The
cells were lysed in 20 volumes of IP buffer at 4 °C and cleared by
centrifugation (10 min 3 20,000 3 g) and filtered through 0.45 mm prior
to immunoaffinity column chromatography. After the entire clarified
cell lysate has passed through the column, the column was developed as
follows: a 10-volume wash with IP buffer followed by 5 volumes of 1 3
PBS, followed by 10 volumes of 0.3 M NaCl in IP buffer, followed by 10
volumes of 0.3 M NaCl, 30% ethylene glycol in IP buffer, followed by 5
volumes of 1 3 PBS, followed by 10 volumes of 1 M MgCl2 in IP buffer,
followed by 5 volumes of 1 3 PBS, followed by elution with 0.1 M glycine,
pH 2.7 (collected in 0.5-ml fractions). The glycine-eluted fractions con-
taining proteins were pooled and concentrated in Amicon microconcen-
trators, and samples of each wash were analyzed by Western blotting.
Enzymatically active Cak1 was recovered in both the NaCl/ethylene
glycol and the MgCl2 eluates, as well as the NaCl wash, indicating that
a substantial proportion of the anti-Cak1 peptide antibodies were low to
moderate in their affinity (Kellogg and Alberts, 1992) and enabling the
purification of Cak1 under nondenaturing conditions.
In Vitro Protein Kinase Assays—MG-63 and TE-85 cells were cul-
tured, lysed, and clarified as described for immunoprecipitation. After
aliquots of the clarified lysates were incubated either without primary
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antibodies (control) or with anti-Cak1 antibodies (IgG fraction), the
resulting immune complexes were collected and washed as described
above. Each pellet was resuspended in 50 ml of kinase assay buffer and
incubated with 100 mM [32P]ATP (specific activity at 500-1000 cpm/
pmol), 10 mM magnesium acetate, with and without recombinant rena-
tured Cdk substrates, for 30 min at 30 °C with continuous agitation.
The kinase reactions were terminated by the addition of 5 3 SDS
sample buffer; the proteins were denatured by heating at 95 °C for 5
min and then analyzed by SDS-PAGE, Western blotting, and autora-
diography at 270 °C using Lightning Plus or Quanta III intensifying
screens (Dupont).
Protein Fragmentation and Microsequence Analysis—Cak1-associ-
ated proteins were isolated using Anti-Cak1 antibodies and immunoaf-
finity chromatography. Hela S-3 cells (7 g wet weght) were lysed in 20
volumes of ice-cold IP buffer, cleared by centrifugation, and filtered
through 0.45 mm prior to application to the immunoaffinity column.
After extensive washing, the bound proteins were eluted with low pH
buffer (100 mM glycine, pH 2.7). The eluate was pooled and concen-
trated in Amicon Centricon 10 microconcentrators, and samples were
analyzed by SDS-PAGE and Western blotting prior to protein microse-
quencing. The concentrated eluates from the immunoaffinity column
were loaded directly onto a 12% SDS-polyacrylamide gel for electro-
phoresis as described previously. The gel was stained with 0.05% Coo-
massie Brilliant Blue (Sigma), destained, and soaked in distilled water
for 1 h. The protein band, migrating at approximately 35 kDa, was
excised from the gel and subjected to in-gel digestion with Achro-
mobacter endoprotease K for 24 h at 30 °C, as described previously
(Kawasaki et al., 1990). The digests were cleared by centrifugation
followed by filtration through a 0.22-mm membrane (Ultrafree-MC,
Millipore). The peptides were separated by reverse-phase HPLC
(Hewlett Packard 1090) on a Vydac C18 column (2.1 3 250 mm, 5 mm,
300 A) attached to an anion-exchange precolumn (Brownlee GAX-013,
3.2 3 15 mm) and eluted with an acetonitrile gradient as their absorb-
ances at 214, 280, 295, and 550 nm were monitored. Amino acid
sequencing was performed on an automated microsequencer (ABI
model 470) with an on-line HPLC (ABI model 120A) for the analysis of
phenylthiohydantoin-tagged amino acids.
RESULTS
Characterization and Application of Specific Anti-Cak1 An-
tibodies—The high degree of homology conserved within the
family of Cdc2-related enzymes (i.e. Cdks) necessitated the
development of specific immunochemical reagents. Therefore,
we developed antipeptide antibodies directed against a unique
sequence in the C terminus of (Hs)Cak1 (see Fig. 1A). The
resulting antipeptide antibodies readily recognized the recom-
binant protein on Western blots (Fig. 1B), exhibiting detection
limits of ;0.1 ng under standard conditions (see “Experimental
Procedures”). The capability of these anti-Cak1 antibodies to
detect the p42cak1 protein in Western blots of crude lysates of
various rat and human cell lines was demonstrated in Fig. 1C.
The levels of p42cak1 protein in the various cell lines were
estimated to be ;1 ng of protein kinase subunit/10 mg of cell
lysate, which is remarkably in close agreement to the levels
(1:10,000) predicted by protein purification studies (Williams et
al., 1994; Fisher and Morgan, 1994). Comparatively high levels
of p42cak1 were detected in rat and human osteosarcoma cells
(Fig. 1C), both of which exhibited additional immunoreactive
protein band(s) at ;44 and ;55 kDa, possibly representing
alternatively spliced or closely related isoforms of the Cak1
kinase (see Shuttleworth et al. (1990)).
The anti-Cak1 antibodies efficiently precipitated the native
protein, enabling further studies of Cak1-associated proteins.
Immunoprecipitation experiments of [35S]Met/Cys-labeled os-
teosarcoma cells revealed two prominent proteins, at 37 and 35
kDa, respectively, that associate with Cak1 in potentially stoi-
chiometric amounts (Fig. 2A), and the former has been identi-
fied as cyclin H (Mäkelä et al., 1994; Fisher and Morgan, 1994).
A heavily labeled protein of 80–90 kDa, as well as several
proteins in the 50–55-kDa range, were also identified as po-
FIG. 1. Design and application of specific anti-Cak1 antibodies. A, alignment of the C-terminal domains adjacent to the conserved
subdomain XI of identified human Cdks. The primary structure of the synthetic peptide used to raise specific anti-Cak1 antibodies is underlined.
Double underlined is the putative PKA phosphorylation site located within the bipartite nuclear localization motif. B, titration of Cak1 detection
upon Western blotting by polyclonal anti-Cak1 antibodies raised against the immunizing peptide. Note comparative cross-reactivity with Xenopus
M015, which exhibits a similar but nonidentical C terminus (see Shuttleworth et al., 1990). C, Western blotting of cell lysates obtained from a
variety of normal and neoplastic cell lines with affinity-purified anti-Cak1 antibodies. Each lane was loaded with 10 mg of protein of the respective
detergent lysate: normal rat kidney fibroblast (NRK-49F), rat osteosarcoma (UMR-106), normal human diploid fibroblast (WI-38), human
osteosarcoma (MG-63, SAOS-2, TE-85, U2OS), Ewings sarcoma (EW-1), mammary carcinoma (MDA-MB), epithelioid carcinoma (A-431), pancre-
atic carcinoma (HS-766T). While the anti-Cak1 antibodies detected a protein of the expected size (p42cak1) in all samples, additional bands of
immunoreactivity migrating at ;36 and ;55 kDa were pronounced in the majority of the human cancer-derived cell lines (see lanes 5–11). Also
note the additional band at ;43 kDa that appears to be unique to the rat osteosarcoma cell line (lane 2).
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tential Cak-associated proteins. The specificity of the immuno-
precipitation assay was confirmed by the use of affinity-puri-
fied antibodies (Fig. 2A, lane 3) and peptide-blocked antibodies
(Fig. 2A lane 4), as well as minus antibody controls. Western
blotting of the immunoprecipitates confirmed that p42cak1 was
the only immunoreactive protein recognized by these antibod-
ies (Fig. 2A, lanes 5–8) further indicating that the profile of
proteins represented are physically associated with Cak1 (see
“Discussion”). Further studies of Cak1-associated proteins in
highly synchronized MG-63 osteosarcoma cells (Fig. 2B) con-
firmed the constitutive expression of p42cak1 (Wu et al., 1994)
and demonstrated that both p37 (i.e. Cyclin H) and p35 remain
constant in their association with Cak1 throughout the cell
cycle. However, the relative abundance of the 90–95-kDa pro-
tein, as well as its electrophoretic migration pattern, appears to
shift as cells proceed from G1 to S phase.
Isolation and Characterization of a Cak1-associated Pro-
tein—The immunoprecipitation experiments were scaled up in
the form of immunoaffinity column chromatography in which
7 g (;7 3 109 cells) of Hela cells were lysed and applied to an
anti-Cak1 affinity matrix. The column effectively depleted a
majority of the Cak1 and Cak1-associated proteins (see Fig. 3).
After extensive washing and elution of bound proteins (see
“Experimental Procedures”), the adsorbed immune complexes
were analyzed by SDS-PAGE. As shown in Fig. 3, lane 5, the
amounts of p37 and p35 appear similar. The p35 protein band
was excised from the gel and subjected to endoproteinase K
digestion prior to analysis by HPLC fractionation and micro-
sequencing of the resultant peptide fragments. Five polypep-
tide sequences were obtained, as follows: peptide K17,
-EEALYEYQK-; peptide K6, -PQDLAAGGYK-; peptide K23,
-QAFLDELETSSK-; peptide K10, -M(G/S)QHISLAPI(H)-; and
peptide K12, -QPFYGLT(S)-. The amino acids within parenthe-
ses represent an uncertain reading near the detection limits of
the instrument. Three of the five polypeptides aligned well with
sequences of identified cyclins, as shown in Fig. 4. These se-
quences lie within the designated cyclin box region (Hunt,
1991), with closest similarity to the yeast cyclinMcs2, followed
by human cyclin H and human cyclin C, respectively.
Immunoaffinity Purification and Elution of Enzymatically
Active Cak1 under Nondenaturing Conditions—The anti-Cak1
antibodies, which selectively immunoprecipitate Cak1 and its
associated proteins from cell lysates, were used to construct
immunoaffinity chromatography matrices for the purification
of active Cak1 complexes from Hela S-3 cells. After extensive
washing of the affinity column, immunopurified Cak1 com-
plexes were eluted from the column under a series of increas-
ingly harsh elution conditions to ascertain the overall affinity
of the anti-peptide antibodies and to obtain a purified fraction
of enzymatically active Cak1 complexes under nondenaturing
conditions. As shown in Fig. 5A, the immunoaffinity matrix
depleted the majority of the Cak1 present in Hela cell lysates
(lanes 1 and 2). A significant amount of bound Cak1 could be
eluted from the affinity matrix with buffer containing 0.3 M
NaCl and 30% ethylene glycol (lane 4), while the bulk of the
remaining bound Cak1 could be eluted by 1 M MgCl2 (lane 5),
leaving only traces of the kinase (lane 6) on the column. The
FIG. 2. Identification of Cak1-associated proteins in human
osteosarcoma cells. A, asynchronous cultures of TE-85 osteosarcoma
cells were metabolically labeled with [35S]Met/Cys, and the washed
cells were lysed and immunoprecipitated with anti-Cak1 antibodies
(IgGs, lanes 2 and 6) or affinity-purified anti-Cak1 antibodies (Affi,
lanes 3 and 7). The specificity of the immunoprecipitation was con-
firmed by minus antibody (Control, lanes 1 and 5) and by precipitation
with peptide-blocked primary antibodies (1Peptide, lanes 4 and 8). The
resulting immune complexes were analyzed by autoradiography (left
panel). Of particular interest are the three prominent bands migrating
at ;35, 37, and 42 kDa, respectively, as well as several proteins of
higher molecular mass. Western analysis of the resulting immune com-
plexes (right panel) identifies the 42-kDa protein as Cak1 and further
indicates that p35 and p37 are Cak1-associated proteins. B, cell cycle
dependence was examined in highly synchronized MG-63 cells (Carbon-
aro-Hall et al., 1993), which were lysed and analyzed by immunopre-
cipitation with (1) and without (2) anti-Cak1 antibodies. Based on
SDS-PAGE and autoradiography (left panel), Cak1 (p42) appears to be
constitutive in the cell cycle, as are its associated proteins, p37 (i.e.
cyclin H), p35, p55, and p90, although p90 undergoes appreciable shifts
in electrophoretic mobility in the transition from G1 to S phase. Western
analysis (right panel) identifies the Cak1-associated p37 as cyclin H.
FIG. 3. Immunoaffinity chromatography isolates Cak1 com-
plexes from Hela cell lysates. Approximately 7 g (wet weight) of
frozen Hela cells were lysed, filtered, and applied to an anti-Cak1
affinity matrix, as described under “Experimental Procedures.” The
affinity-purified protein complexes were eluted with 100 mM glycine,
pH 2.7 (lane 4), followed by Western analysis of the various fractions
and eluates for p42/Cak1 immunoreacted with the anti-Cak1 antibod-
ies. The efficiency of Cak1 in depleting p42/Cak1 from the crude lysates
is shown (compare lanes 1 and 2). Protein staining of part of the eluate
indicate the relative abundance of the three proteins bands of particular
interest: p42, identified as Cak1; p37, identified as Cyclin H; and p35,
which remains to be characterized. The band of protein at ;35 kDa was
excised and subjected to limited proteolysis by endoprotease K, followed
by HPLC separation of the digests and microsequencing of the resulting
peptides, as described under “Experimental Procedures.” Five peptide
sequences were obtained, as shown. (Parentheses indicate uncertainty.)
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enzymatic activity of the immunoaffinity-purified Cak1 was
confirmed by use of the Cdc2 Thr-161-immobilized peptide
substrate assay (Williams et al., 1994), in which the NaCl/
ethylene glycol eluates exhibited a 2-fold higher kinase activity
(per ml) than the MgCl2 eluates, revealing an apparent specific
activity approximately 10-fold higher (data not shown). In
agreement with studies of purified preparations (Williams et
al., 1994), substitution of the histidine residue with an alanine
in the test peptide reduced the peptide kinase activity by ;90%
(data not shown), confirming that the adjacent histidine resi-
due may be an important determinant of Cak1 substrate
specificity.
The immunoaffinity-purified Cak1 preparations exhibited
phosphorylation of the p42cak1 monomer in in vitro kinase
assays (Fig. 5B), resulting presumably from autophosphoryla-
tion, although heterologous phosphorylation by a tightly asso-
ciated Cak1 kinase cannot be ruled out. Furthermore, the
immunopurified Cak1 preparations were active in phos-
phorylating Cdc2 and Cdk2, but not Cdk2/160-Ala, even in the
presence of recombinant cyclin A (Connell-Crowley et al.,
1993). Phosphorylation of both Cdc2 and Cdk2 was markedly
increased by the addition of recombinant Cyclin A to the reac-
tion mixtures. In agreement with recent reports using purified
materials (Dorée and Galas, 1994), but in contrast to those
using reconstituted Cak1zcyclin H complexes (Fisher and Mor-
gan, 1994), these immunopurified Cak1 preparations phospho-
rylated both monomeric Cdc2 and Cdk2 but not Cdk4 (see Fig.
5C), suggesting that they may include regulatory and/or tar-
geting subunits that are missing from the reconstituted
Cak1zcyclin H complexes.
DISCUSSION
Subunit configuration and site-specific phosphorylation re-
actions regulate the enzymatic activities of the cyclin-depend-
ent protein kinases p34cdc2 and p33cdk2. Our previous studies of
Cdc2 phosphorylation led to the isolation (Williams et al.,
1993a, 1993b) and molecular cloning (Wu et al., 1994) of the
human Cdk-activating kinase, p42cak1, a homologue of Xenopus
MO15 (Shuttleworth et al., 1990) that targets the phosphoregu-
latory sites within subdomain VIII of Cdc2 and Cdk2 (Solomon,
1993, 1994; Solomon et al., 1993; Poon et al., 1993). The striking
FIG. 4. Amino acid sequence alignment of peptides derived
from the Cak1-associated 35-kDa protein with identified cyc-
lins. The amino acids sequences of three of the five peptides obtained
are aligned with three of their nearest cyclin relatives: the yeast Mcs2
(Molz and Beach, 1993), the human cyclin H (Fisher and Morgan, 1994),
and human cyclin C (Fisher and Morgan, 1994). The homology to Mcs2
is greater than the homology to human cyclin H and human cyclin C,
suggesting that p35 may be a human homologue of the yeast cyclin,
Mcs2.
FIG. 5. Immunoaffinity chromatography yields active Cak1
complexes from Hela cell lysates. A, approximately 7 g (wet weight)
of frozen Hela cells were lysed, filtered, and applied to an anti-Cak1
affinity matrix, as described under “Experimental Procedures”; the
column was washed with 300 mM NaCl (lane 3), and the affinity-
purified protein kinase complexes were eluted sequentially with 300
mM NaCl plus 30% ethylene glycol (lane 4), 1 M MgCl2 (lane 5), and 100
mM glycine, pH 2.7 (lane 6), followed by Western analysis of the eluates
for p42cak1. The efficiency of Cak1 depletion from the crude lysates
(compare lanes 1 and 2), taken together with the elution of the bulk of
the bound enzyme under nondenaturing conditions, indicates that the
anti-Cak1 antibodies were uniformly low to moderate in their affinity.
B, immunoaffinity-purified Cak1 (MgCl2 fractions) were utilized as a
source of enzyme for in vitro kinase assays performed in the presence
(1) or absence (2) of recombinant cyclin A with either glutathione
S-transferase-Cdc2, glutathione S-transferase-Cdk2, or an Ala-160 mu-
tant of glutathione S-transferase-Cdk2 as substrates for Cak1. The
migration of the respective recombinant proteins upon SDS-PAGE was
visualized by Coomassie Blue stain (arrows, left panel), while the kinase
reaction was evaluated by autoradiography (right panel). Under these
conditions, both Cdc2 and Cdk2 are more readily phosphorylated by
Cak1 in the presence of cyclin A (compare lanes 1 and 2 and lanes 3 and
4), while the Cdk2-A mutant was enzymatically active toward cyclin A
(see lane 5) without Thr-160 phosphorylation (Connell-Crowley et al.,
1993). Note discernable autophosphorylation of immunopurified
p42cak1. C, comparative utilization of recombinant Cdc2, Cdk2, and
Cdk4 as Cak1 substrates was examined by incubation of the respective
recombinant Cdk substrates in the presence (1) or absence (2) of
immunoaffinity-purified Cak1 followed by SDS-PAGE and autoradiog-
raphy. Under these conditions, monomeric Cdc2 and Cdk2, but not
Cdk4 was readily phosphorylated by Cak1 complexes.
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homology of (Hs)Cak1 to (Hs)Cdc2 (Wu et al., 1994), together
with the identification of Cyclin H as a prospective regulatory
partner (Fisher and Morgan, 1994; Mäkelä et al., 1994), sup-
port the concept that Cdks participate in a vectorial kinase
cascade.
Recent studies have indicated that Cak1zMO15, by associa-
tion with the TFIIH transcription factor, may also function as
the RNA polymerase II C-terminal domain kinase (Roy et al.,
1994; Feaver et al., 1994), linking Cak1 activity to the control of
transcription, as well as cell cycle progression. Taken together
with the seminal observation that M015 mRNA is, by virtue of
alternative start sites (Shuttleworth et al., 1990), capable of
yielding two different forms of the kinase, these findings raise
the possibility that structurally and functionally distinct iso-
forms of Cak1 may participate in transcriptional regulation vis
à vis cell cycle control pathways. Alternatively, the association
of Cak1 with multiple regulatory subunits (i.e. cyclin-like pro-
teins) may provide additional regulatory and or targeting fea-
tures, as has been demonstrated for Cdk2 (see Peeper et al.
(1993)).
Immunoaffinity Purification of Enzymatically Active Cak1—
Anti-Cak1 antibodies afforded the precipitation of Cak1-asso-
ciated proteins (see Fig. 2A), revealing proteins at 37 (cyclin H)
and 35 kDa that appear to be stoichiometric, and a series of
higher molecular mass proteins at ;80–90 and 50–55 kDa that
may correspond to the high molecular mass complexes ob-
served upon extensive purification of Cak1 (Wu et al., 1994;
Williams et al., 1994). Indeed, the report that Cak1 associates
with the TFIIH transcription-DNA repair complex and, by hy-
perphosphorylation, regulates the function of RNA polymerase
II (Roy et al., 1994; Feaver et al., 1994) supports the concept
that these coprecipitated proteins, in addition to Cdks, may be
physiological substrates for Cak1 (Williams et al., 1994).
The utility of the antipeptide antibodies in immunoprecipi-
tation studies was further exploited in immunoaffinity chroma-
tography. The ability of these antipeptide antibodies to release
enzymatically active Cak1 complexes under nondenaturing
conditions indicate that the bulk of the precipitable antibodies
within the IgG fractions were low to moderate in affinity
(Kellogg and Alberts, 1992). Immunoaffinity-purified Cak1
complexes were capable of phosphorylating monomeric Cdc2
and Cdk2, but not Cdk4 (see Fig. 5C), which is consistent with
observations based on purified materials (Williams et al., 1994;
Dorée and Galas, 1994) but is strikingly different from the
substrate specificity of reconstituted Cak1 (Fisher and Morgan,
1994), indicating additional regulatory features that remain to
be identified.
Identification of a New Cak1 Subunit—Cak1 is associated
with at least two auxiliary subunits, p37Cyclin H and a slightly
lower molecular mass subunit previously designated p35
(Mäkelä et al., 1994). Metabolic labeling of cellular proteins
with [35S]methionine followed by immunoprecipitation using
specific anti-Cak1 antibodies revealed a number of Cak1-asso-
ciated proteins: (i) a high molecular mass complex (;90 kDa),
(ii) a series of multiple protein bands at ;55 kDa, and (iii) two
Cak1-associated proteins at ;35 and 37 kDa, respectively. The
37-kDa protein has previously been identified as cyclin H
(Mäkelä et al., 1994; Fisher and Morgan, 1994). In this study,
we further characterized the primary structure of the 35-kDa
protein. Following SDS-PAGE, protein isolation, endoprotease
K digestion, and HPLC fractionation of the resultant peptides,
microsequence data was obtained. The results indicate that the
35-kDa protein represents a cyclin-like regulatory subunit that
associates either directly or indirectly with Cak1. The novel
regulatory subunit, represents a new member in a growing
family of cyclin-like proteins that are related to cyclin C (see
Fig. 4). Sequence alignment of three of the five peptides indi-
cates appreciable homology to the yeast Mcs2 protein (a yeast
cyclin) as well as to human cyclin H and cyclin C, which
suggests that p35 may be a human homologue of theMcs2 gene
of S. pombe (Molz and Beach, 1993). The finding that Cak1 may
form complexes with multiple regulatory partners (i.e. cyclin-
related subunits) is reminiscent of other cyclin-dependent ki-
nases, such as Cdc2 and Cdk2, that associate with different
partners in the performance of specific functions.
These studies, taken together with other recent findings,
support the concept that the Cdk-activating kinase system is
highly regulated and multifunctional. The suggestion that
Cak1 may be a primary RNA polymerase II C-terminal domain
Kinase (Feaver et al., 1994; Roy et al., 1994) points to a major
role in transcriptional regulation. CAK activity is associated
with the transcription initiation factor TFIIH, which also func-
tions in nucleotide excision repair (Hanawalt, 1994). Thus, in
addition to its classic role as the upstream activator for Cdks,
and hence crucial to cell cycle progression, Cak1 appears to
have a function in DNA transcription, fidelity, and repair
mechanisms. Thus, the demonstration that the Cak1 catalytic
subunit forms stable complexes with multiple cyclin-like regu-
latory partners may provide a mechanistic basis for substrate
targeting and/or specificity (see Peeper et al., 1993) that would
be predicted for a multifunctional enzyme system.
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